Government and Private Investments Fueling the High Throughput Screening Market
The COVID-19 pandemic highlighted the urgent need for rapid drug discovery, and High Throughput Screening (HTS) played a pivotal role in accelerating antiviral research. Beyond COVID-19, HTS is now widely applied in developing treatments for various infectious diseases.
The High Throughput Screening Market is expected to achieve USD 44.69 billion by 2032, expanding at a CAGR of 7.80% from 2023–2032. Infectious disease research remains one of its fastest-growing application areas.
HTS platforms can screen thousands of antiviral, antibacterial, and antifungal compounds against pathogens quickly. This capability is essential in responding to emerging infectious threats where traditional drug discovery timelines are too long.
Additionally, HTS combined with AI-driven predictive modeling allows researchers to identify compounds with higher efficacy and lower resistance potential. The technology is also aiding vaccine development, as it helps identify immunogenic molecules faster.
As global concerns over antibiotic resistance and emerging viral outbreaks continue, HTS will play a critical role in ensuring timely drug discovery for infectious diseases.
👉 Learn more about the High Throughput Screening Market.